Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 07, 2022

SELL
$0.24 - $4.27 $809 - $14,406
-3,374 Reduced 5.2%
61,464 $14,000
Q2 2022

Aug 09, 2022

BUY
$0.37 - $0.71 $14,887 - $28,568
40,237 Added 163.56%
64,838 $25,000
Q1 2022

May 17, 2022

SELL
$0.5 - $1.15 $75,338 - $173,278
-150,677 Reduced 85.96%
24,601 $16,000
Q4 2021

Feb 17, 2022

BUY
$0.91 - $1.5 $60,932 - $100,438
66,959 Added 61.82%
175,278 $179,000
Q3 2021

Nov 12, 2021

BUY
$1.39 - $3.47 $150,563 - $375,866
108,319 New
108,319 $151,000
Q2 2021

Sep 17, 2021

SELL
$3.24 - $6.92 $44,057 - $94,098
-13,598 Closed
0 $0
Q1 2021

May 19, 2021

BUY
$6.34 - $12.68 $86,211 - $172,422
13,598 New
13,598 $93,000

Others Institutions Holding VYNE

About VYNE Therapeutics Inc.


  • Ticker VYNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,005,600
  • Market Cap $176M
  • Description
  • VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, whi...
More about VYNE
Track This Portfolio

Track Virtu Financial LLC Portfolio

Follow Virtu Financial LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtu Financial LLC with notifications on news.